MET activation by its ligand, hepatocyte growth factor (HGF), triggers a cascade of downstream signalling pathways, including the PI3K/AKT, RAS/MAPK, and STAT3 pathways, which are essential for driving oncogenesis, tumour progression, and metastasis (Reviewed in: (Birchmeier et al, 2003; Boccaccio and Comoglio, 2006; Comoglio et al, 2018)). The gene discussed is MET; the disease is neoplasm.